Study of Low-Dose Droperidol Effects on Heart QTc Interval in Emergency Department Patients

What this Trial Is About

This research aims to evaluate how a low dose of droperidol affects the QTc interval in patients visiting the emergency department ED. The study focuses on adults 18 years and older who are monitored in cardiac beds and receive 2.5 mg of droperidol intravenously. Researchers want to find out if this dose causes any significant changes in the QTc interval, which is an important measure of heart electrical activity. Participants will have an ECG recorded before and then again between 5 and 30 minutes after receiving the droperidol dose. The study will document any changes in QTc interval between these two ECGs. The post-droperidol ECGs will not impact the patients medical care in the ED and will not be reviewed in real time for treatment decisions. During the study, patients will be monitored with ECGs and their medical records reviewed to confirm timing of droperidol administration. Researchers will measure the percentage of patients who experience a clinically significant QTc increase of 20 ms or more, as well as the average QTc change across the group. The study will continue until September 2026, with participants involved during their emergency department visit.

Droperidol and QTc Interval Changes in ED Patients